Rosetta Genomics (ROSG) Announces Validation Study Published
Tweet Send to a Friend
Up)
Momentum mover, Rosetta Genomics Ltd. (NASDAQ: ROSG) announced data from studies of miRview mets in patients with Cancer of Unknown and Uncertain Primary were published online in The Oncologist in an article titled, "A second generation microRNA-based assay for diagnosing tumor tissue origin: An improved microRNA-based mets assay."
The study demonstrated the ability of the miRview mets assay to identify 42 tumor types with high accuracy and to maintain the same performance in samples from patients clinically diagnosed with CUP, showing an 88% concordance with the clinico-pathological evaluation of the patients.
The article is here
Shares of ROSG are down 7 percent today following a stock offering, but is up 844% since May 16th.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The study demonstrated the ability of the miRview mets assay to identify 42 tumor types with high accuracy and to maintain the same performance in samples from patients clinically diagnosed with CUP, showing an 88% concordance with the clinico-pathological evaluation of the patients.
The article is here
Shares of ROSG are down 7 percent today following a stock offering, but is up 844% since May 16th.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- Tesla (TSLA) Pushes Back Into Positive Territory on DOE Loan Repayment
- Mannkind (MNKD) Cools Down after 2 Day Gains
Create E-mail Alert Related Categories
Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
